SecBot SecBot
424B5 ·Filed Aug 6, 2026

CGON

CG Oncology, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001193125-26-336792
Actionable Insight ▼ Bearish

The massive ATM upsizing signals aggressive capital raising, likely ahead of regulatory and commercial milestones for cretostimogene. The potential for ongoing dilution over the coming weeks/months will weigh on the stock. Monitor daily ATM sales volumes and any news on cretostimogene's regulatory progress (BLA submission/approval). A significant catalyst could offset the overhang, but absent positive news, expect continued selling pressure.

DirectionBearish
Confidencehigh
Horizonweeks

cretostimogene

▲ Bullish Named in this 424B5
Impact
Phase
Phase 3
Time to market
BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
Next catalyst
None dated

What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$74.85
T+0 close · Aug 6, 2026 · via day close
Latest settled
−15.20%
T+60 · $63.47
Vs SPY
−13.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $74.85entry
  2. T+1 · 3mo ago +0.33%α −0.28% · $75.10
  3. T+5 · 3mo ago −0.19%α −1.40% · $74.71
  4. T+20 · 3mo ago −0.69%α −1.29% · $74.33
  5. T+60 · 18d ago −15.20%α −13.78% · $63.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology upsized its at-the-market (ATM) equity offering by $500M to a total of $1.05B, after already selling $550M in gross proceeds via 10.8M shares. The additional capacity represents potential dilution of up to ~7.8% of shares outstanding at current prices, with proceeds earmarked for general corporate purposes including R&D and commercialization of its lead candidate, cretostimogene. The massive capital raise signals aggressive funding needs and will likely pressure the stock as the market absorbs the supply over time.

Key Facts

  • ATM offering capacity increased by $500M to a total of $1.05B (Amendment No. 2 to Prospectus).
  • Already sold 10,800,525 shares for gross proceeds of $550M under the existing ATM agreement.
  • At the August 5, 2026 closing price of $72.42, the additional $500M capacity represents up to ~6.9M shares, or ~7.8% of the 88.0M shares outstanding as of March 31, 2026.
  • Proceeds intended for general corporate purposes, including R&D and commercialization of cretostimogene.
  • New investors would experience immediate dilution of $55.92 per share at the assumed offering price of $72.42.
  • Jefferies LLC acts as sales agent with a 3.0% commission on gross proceeds.

Financial Impact

Up to $500M in additional common stock sales, potentially diluting existing shareholders by ~7.8% at current prices. Total ATM capacity now $1.05B.

dilutionshare countcash

Risk Factors

  • Substantial dilution from the full $500M ATM tranche if sold at current prices.
  • Lack of near-term revenue or profitability increases reliance on equity financing.
  • Market may interpret aggressive capital raising as a sign of higher cash burn or delayed milestones.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (CGON), Batch item 10001193125-26-336792
Document: d178600dexfilingfees.htm0001193125-26-336792
Document: 0001193125-26-336792-index-headers.html0001193125-26-336792
Document: 0001193125-26-336792-index.html0001193125-26-336792
Document: 0001193125-26-336792.txt0001193125-26-336792
424B5 Filing (CGON), Batch item 60001193125-26-336792

Track record

25 reports on CGON

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Viewing Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026